Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

NCT00653328 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Abbott (drug manufacturer) discontinued manufacture of ABT-627

Conditions

Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions

DRUG: atrasentan hydrochloride
DRUG: doxil

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]